Navigation Links
ConvaTec Introduces Enhanced Flexi-Seal® SIGNAL® FMS
Date:6/12/2012

SKILLMAN, N.J., June 12, 2012 /PRNewswire/ -- ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, announced today the launch of enhanced Flexi-Seal® SIGNAL® Fecal Management System (FMS). 

Already available in Canada and now in the U.S., Flexi-Seal® SIGNAL® FMS has been enhanced with nurse-inspired features to respond to clinicians' needs.

In addition to the original innovative design and SIGNAL™ indicator, Flexi-Seal® SIGNAL® FMS enhancements include:

  • A sampling port designed for safe and easy stool collection and to help decrease risk of exposure to infectious stool
  • A simple medication delivery process to allow prescribed medication rectally via the irrigation port, without complicating the use of the device
  • An extended catheter that adapts to a range of bed sizes and accommodates a variety of patient heights and weights

About the Flexi-Seal® FMS family of fecal management systems

Flexi-Seal® FMS is used by more nurses and hospitals than any other fecal management system in the world.(1)

Flexi-Seal® FMS is indicated for patients with little or no bowel control and liquid or semi-liquid stool, and can be used for up to 29 consecutive days. This temporary containment device for patients with acute fecal incontinence was designed to safely and effectively divert fecal matter, protect patients' wounds from fecal contamination, and reduce the risk of skin breakdown and spread of infection. 

Other key features of Flexi-Seal® SIGNAL® FMS include:

  • Unique SIGNAL™ indicator that pops to assist clinicians in determining when the device's retention balloon is filled to an appropriate volume -- providing confidence that the product is filled for its optimum performance -- thus creating a safe and effective seal for their patients' protection.*
  • A soft, low-pressure balloon designed to aid easy insertion and removal and minimize the chance of tissue necrosis.
  • A closed-end charcoal-filtered collection bag which is designed to contain and lock in odor, and provides an effective barrier to C. difficile transmission, thus helping to minimize the risk of cross-contamination.(2)  
  • A blue, easy to locate finger pocket designed for simple single-finger insertion and an increased irrigation lumen to aid in the administration of fluid to facilitate irrigation.
  • A versatile strap designed to securely lock onto an open bed frame, also helping to minimize the risk of contamination that might result from spillage. 
  • Does not contain natural rubber latex components.

Clinical Evidence

Flexi-Seal® SIGNAL® FMS has been scientifically proven in vitro to contain the spread of C. difficile.(2)

A prospective, 42-patient clinical study was conducted to evaluate the safety and performance of Flexi-Seal® FMS in subjects with liquid or semi-liquid diarrhea and incontinence. Key findings include:(3)

  • Rectal mucosa was healthy after Flexi-Seal® FMS use for all patients who had baseline and follow-up endoscopy.
  • 92% of patients had their skin condition maintained or improved.
  • 83% of caregivers reported that Flexi-Seal® FMS improved fecal incontinence control, was efficacious, and time efficient.

* Signal indicator could pop before 45mL if the space available for the balloon is smaller than the balloon. Filling should stop when the indicator pops out and stays out. More than 45mL is never to be added to the balloon.

About ConvaTec

ConvaTec is a leading developer and marketer of innovative medical technologies that have helped improve the lives of millions of people worldwide. With four key focus areas – Ostomy Care, Wound Therapeutics, Continence and Critical Care, and Infusion Devices – ConvaTec products support healthcare professionals from the hospital to the community health setting. For more information, please visit www.convatec.com.

(1) HPIS. Q2 2009. Moving Annual Total (MAT) Fecal Control Category. Data on file, ConvaTec.

(2) Jones S, Towers V, Welsby S, Wishin J, Bowler P. Clostridium difficile Containment Properties of a Fecal Management System: An In Vitro Investigation. Ostomy Wound Management, 2011;57(10):38-49.

(3) Padmanabhan A, Stern M, Wishin J, Mangino M, Richey K, DeSane M. Clinical evaluation of a flexible fecal incontinence management system. Am J Crit Care, July 2007;16:384-393.

®/™ indicates trademarks of ConvaTec Inc.

© 2012 ConvaTec Inc.                                                                                         


'/>"/>
SOURCE ConvaTec
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ConvaTec Announces Acquisition of AbViser Medical, LLC
2. ConvaTec Donates $10,000 To AAWC Global Volunteers Program Through SAWC Walk For Wellness
3. IDEV Technologies Introduces SurePath™ Guidewires
4. Velos, Inc. Introduces Mobile App for Oncology Adverse Events and Graft-Versus-Host Disease at 2012 ASCO Annual Meeting
5. Rochester Medical Introduces Magic3® Coude Tip Hydrophilic Intermittent Catheter
6. Richard Wolf Medical Instruments introduces groundbreaking 5514 Endocam Performance HD
7. Pernix Therapeutics Introduces Omeclamox-Pak®, First Product in Gastroenterology Portfolio
8. IRIDEX Introduces Non-Invasive MicroPulse™ Therapy for Glaucoma
9. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
10. PharMEDium Highlights Enhanced Labeling for ICU Services at Critical Care Expo
11. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and ... This is in conjunction with this morning,s announcement of ... Thrombosis and Nutritional Insufficiency businesses. Cardinal Health ... operations will be at the bottom of its previous ...
Breaking Medicine Technology:
(Date:4/25/2017)... , ... April 25, 2017 , ... Back Pain ... and back pain with a reputable physician in their area, announces the launch of ... patient information for patients who are looking for reputable physicians to help them with ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest quality ... problems, I focus on preventative care with all my patients to alleviate possible future issues. ... feel free to contact my office and my trained staff will assist you in any ...
(Date:4/25/2017)... ... ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley Bobrow will be featured ... publish in summer 2017. , Dr. Bobrow, MD, FACEP, FAHA, is an Emergency ... He also serves as Medical Director for the Bureau of Emergency Medical Services and ...
(Date:4/25/2017)... ... , ... Vetoquinol USA® , a world-class developer of ... the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin ... , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and ...
(Date:4/24/2017)... Massachusetts (PRWEB) , ... April 24, 2017 , ... ... will help busy nursing professionals advance their careers. Beginning in the fall of 2017, ... Nursing (BSN) degree in as few as 16 months and for as little as ...
Breaking Medicine News(10 mins):